MCID: MYL005
MIFTS: 67

Myelofibrosis malady

Summaries for Myelofibrosis

Sources:
8Disease Ontology, 43NIH Rare Diseases, 21Genetics Home Reference, 64Wikipedia, 47OMIM, 33MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
NIH Rare Diseases:43 Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by fibrous (scar) tissue. scarring of the bone marrow causes anemia, which can lead to fatigue and weakness, as well as pooling of the blood in abnormal sites like the liver and spleen, causing these organs to swell. although myelofibrosis can occur at any age, it typically develops after the age of 50. in most cases, myelofibrosis gets progressively worse. treatment is aimed at relieving signs and symptoms and may include medications, blood transfusions, chemotherapy, radiation therapy and surgery.    last updated: 8/17/2011

MalaCards: Myelofibrosis, also known as primary myelofibrosis, is related to polycythemia vera and acute leukemia. An important gene associated with Myelofibrosis is JAK2 (Janus kinase 2), and among its related pathways are Akt Signaling and Rho Family GTPases. The drug busulfan and the compounds tyrosine and vegf have been mentioned in the context of this disorder. Affiliated tissues include the bone marrow which results_in bone marrow being replaced by fibrous (scar) tissue, and related mouse phenotypes are hematopoietic system and cellular.

Disease Ontology:8 A myeloma that is located in the bone marrow which results in bone marrow being replaced by fibrous (scar) tissue.

Genetics Home Reference:21 Primary myelofibrosis is a condition characterized by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis.

Wikipedia:64 Myelofibrosis, also known as myeloid metaplasia, chronic idiopathic myelofibrosis, osteomyelofibrosis... more...

Description from OMIM:47 254450

Aliases & Classifications for Myelofibrosis

Sources:
8Disease Ontology, 43NIH Rare Diseases, 22GTR, 21Genetics Home Reference, 10DISEASES, 45Novoseek, 31LifeMap Discovery™, 61UMLS, 35MeSH, 57SNOMED-CT, 47OMIM, 27ICD9CM, 40NCIt
See all sources

Aliases & Descriptions:

myelofibrosis 8 43 22 10 45 31 61
primary myelofibrosis 8 43 21 45 61
agnogenic myeloid metaplasia 8 43 21 45
myeloid metaplasia 43 21 45 61
idiopathic myelofibrosis 43 21 45
chronic idiopathic myelofibrosis 8 21
megakaryocytic myelosclerosis 8 61
myelofibrosis with myeloid metaplasia 21
idiopathic bone marrow fibrosis 8
bone marrow fibrosis 8
myelosclerosis, nos 8
aleukemic myelosis 8
myelosclerosis 8


External Ids:

Disease Ontology8 DOID:4971
MeSH35 D055728
OMIM47 254450
ICD9CM27 238.76
NCIt40 C2862

Related Diseases for Myelofibrosis

Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases in the Myelofibrosis family:

familial myelofibrosis myelofibrosis with myeloid metaplasia, somatic

Diseases related to Myelofibrosis via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 276)
idRelated DiseaseScoreTop Affiliating Genes
1polycythemia vera31.1IFNA2, JAK2, STAT5A, FLT3, THPO, HMGA2
2acute leukemia30.9JAK2, GATA1, STAT5A, THPO, KIT, IL11
3primary polycythemia30.8STAT5A, JAK2, EPO
4splenomegaly30.6JAK2, EPO, MPL, THPO, IFNA2
5vascular disease30.5PF4, FGF2, JAK2
6leukemoid reaction30.5IL3, GATA1
7myeloproliferative disorder30.4THPO, HMGA2, JAK2, IFNA2, GATA1, FLT3
8thrombocytosis30.4THPO, IL11, IL3, PF4, EPO, CD177
9thrombocytopenia30.3IFNA2, THPO, IL11, IL3, PF4, EPO
10megakaryocytic leukemia30.3THPO, IL3, PF4, GATA1, IL11
11chronic myelomonocytic leukemia30.2MPL, FLT3, STAT5A, JAK2, KIT
12pancytopenia30.2IL3, THPO, EPO, MPL
13hypereosinophilic syndrome30.2KIT, IL3
14uremia30.1PF4, EPO, TNFRSF11B, AHSG
15chronic myeloid leukemia30.1THPO, KIT, IL11, IL3, EPO, CD177
16arthritis30.1FGF2, LIF, TNFRSF11B
17myeloid sarcoma30.1KIT, FLT3
18beta thalassemia30.1TNFRSF11B, GATA1, EPO
19refractory anemia29.9IL3, EPO, MPL, FLT3, JAK2, THPO
20systemic mastocytosis29.9KIT, STAT5A, IFNA2, JAK2
21mastocytosis29.9KIT, IFNA2
22wilms tumor29.9FLT3, GATA1
23hypersplenism29.9THPO
24myelodysplastic syndromes29.7THPO, KIT, IL11, IL3, EPO, CD177
25deficiency anemia29.7THPO, IL11, IL3, IFNA2, JAK2, GATA1
26acute lymphocytic leukemia29.7FLT3, GATA1, IL3, MPL, THPO, JAK2
27aplastic anemia29.7THPO, MPL, EPO, IL3, FLT3, IL11
28erythrocytosis29.7IL11, IL3, EPO, CD177, JAK2, MPL
29adenocarcinoma29.7BMP6, LIF, STAT5A, JAK2, PF4, HMGA2
30atherosclerosis29.7AHSG, TNFRSF11B, PF4, FGF2, BMP6, LIF
31thalassemia29.7EPO, GATA1
32hypercalcemia29.7LIF, TNFRSF11B
33renal osteodystrophy29.7TNFRSF11B
34insulin resistance29.7AHSG, JAK2
35precursor t-cell acute lymphoblastic leukemia29.7JAK2, FLT3, IL3, GATA1
36adenoma29.7HMGA2, LIF, STAT5A
37down syndrome29.7JAK2, GATA1, FLT3
38hemorrhagic thrombocythemia29.7CD177
39tuberculosis29.7IL11, PF4
40essential thrombocythemia10.8
41acute panmyelosis with myelofibrosis10.4
42acute myeloid leukemia10.4
43hematopoietic stem cell transplantation10.3
44nocardiosis10.3
45lung lymphoma10.3
46invasive aspergillosis10.3
47aspergillosis10.3
48t-cell leukemia10.2
49pyridoxine deficiency10.2
50rickets10.2

Graphical network of the top 20 diseases related to Myelofibrosis:



Diseases related to myelofibrosis

Clinical Features for Myelofibrosis

Sources:
47OMIM
See all sources

Clinical features from OMIM:

254450

Drugs & Therapeutics for Myelofibrosis

Sources:
5CenterWatch, 42NIH Clinical Center, 6ClinicalTrials, 31LifeMap Discovery™, 61UMLS, 41NDF-RT
See all sources

Approved drugs:

Search CenterWatch for Myelofibrosis

Drug clinical trials:

Search ClinicalTrials for Myelofibrosis

Search NIH Clinical Center for Myelofibrosis

Search CenterWatch for Myelofibrosis

Inferred drug relations via UMLS61/NDF-RT41:

Cell-based therapeutics:


LifeMap Discovery
The database of embryonic development, stem cell research and regenerative medicine
Read about Myelofibrosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myelofibrosis:
Peripheral blood-derived hematopoietic stem cells for treatment of myelofibrosis
Embryonic/Adult Cultured Cells Related to Myelofibrosis:
Peripheral blood-derived hematopoietic stem cells (family)

Genetic Tests for Myelofibrosis

Sources:
22GTR
See all sources

Genetic tests related to Myelofibrosis:

id Genetic test Affiliating Genes
1 Myelofibrosis22

Anatomical Context for Myelofibrosis

Sources:
14FMA
See all sources

FMA organs/tissues related to Myelofibrosis:

14
The bone marrow which results_in bone marrow being replaced by fibrous (scar) tissue

Animal Models for Myelofibrosis or affiliated genes

Sources:
37MGI, 28inGenious Targeting Laboratory
See all sources

Publications for Myelofibrosis

Sources:
51PubMed
See all sources

Articles related to Myelofibrosis:

(show top 50)    (show all 790)
idTitleAuthorsYear
1
SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. (23558523)
2013
2
Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. (24145312)
2013
3
Involvement of TGFI^1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis. (23403314)
2013
4
MAPssbauer spectroscopy of the iron cores in human liver ferritin, ferritin in normal human spleen and ferritin in spleen from patient with primary myelofibrosis: preliminary results of comparative analysis. (23460118)
2013
5
Two novel NPM1 mutations in an acute myeloid leukemia patient transformed from primary myelofibrosis. (22978565)
2013
6
Loss of transfusion dependency following deferasirox treatment of iron overload in a woman with myelofibrosis and spherocytosis - a case report. (23548970)
2013
7
Increased prevalence of autoimmune phenomena in myelofibrosis: relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns. (24080022)
2013
8
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. (23129323)
2013
9
Guideline for the diagnosis and management of myelofibrosis. (22651893)
2012
10
Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis. (23259545)
2012
11
Pruritus in primary myelofibrosis: clinical and laboratory correlates. (22081434)
2012
12
Immunomodulatory agents in myelofibrosis. (22668122)
2012
13
Myelodysplastic syndrome with myelofibrosis transformed to a precursor B-cell acute lymphoblastic leukemia: a case report with review of the literature. (22937321)
2012
14
Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation. (22531490)
2012
15
Myelofibrosis 2012: it's complicated. (23556120)
2012
16
Ruxolitinib for myelofibrosis. (22621634)
2012
17
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). (22180010)
2012
18
Emerging therapeutic options for myelofibrosis: a Canadian perspective. (23119228)
2012
19
Resolution of post-polycythaemic myelofibrosis with a combination of thalidomide and interferon. (22412053)
2012
20
Chronic Childhood Idiopathic Myelofibrosis in Down's Syndrome: A Case Report. (23997458)
2012
21
Advances in the understanding and management of primary myelofibrosis. (21892083)
2011
22
Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. (21691276)
2011
23
Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis. (22035744)
2011
24
Transplantation for myelofibrosis: time for a randomized trial. (21513979)
2011
25
Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. (22086865)
2011
26
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. (21725052)
2011
27
Coexistence of primary myelofibrosis and chronic lymphocytic leukaemia: treatment of two different diseases with one agent. (22829155)
2011
28
Identification of a novel TEL-Lyn fusion gene in primary myelofibrosis. (19710703)
2010
29
Myelofibrosis in children: experience at a single tertiary care center in India. (20670165)
2010
30
Myelofibrosis involving lymph node: a novel cytogenetic abnormality in a mimicker of mesenchymal neoplasm. (19669186)
2009
31
The decrease of JAK2 V617F allele burden in leukemia transformation of an elderly patient with myelofibrosis. (19328546)
2009
32
A novel cytogenetic abnormality in primary myelofibrosis. (19737657)
2009
33
MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia. (19811223)
2009
34
Elevated TNF-alpha and LDH without parathormone disturbance is associated with diffuse osteolytic lesions in leukemic transformation of myelofibrosis. (17976926)
2008
35
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. (17488875)
2007
36
The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study. (17875526)
2007
37
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). (16675707)
2006
38
JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. (16563504)
2006
39
Modern management of myelofibrosis. (15725078)
2005
40
Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. (15833861)
2005
41
Myelofibrosis-associated massive splenomegaly: a cause of increased intra-abdominal pressure, pulmonary hypertension, and positional dyspnea. (16184577)
2005
42
Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents. (12886259)
2003
43
Idiopathic myelofibrosis associated with classic polyarteritis nodosa. (12688329)
2003
44
The therapy of myelofibrosis: targeting pathogenesis. (12430941)
2002
45
Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera. (12270061)
2002
46
Hypertrichosis due to porphyria cutanea tarda associated with blastic transformation of myelofibrosis. (10583184)
1999
47
Combination therapy with recombinant human erythropoietin, interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in idiopathic myelofibrosis. (8701705)
1996
48
Avian monocytic leukemia cells release fibroblast growth factor: implications to associated myelofibrosis. (3866125)
1985
49
Response to pyridoxine hydrochloride in refractory anemia due to myelofibrosis. (707525)
1978
50
Pyruvate kinase deficiency anemia with terminal myelofibrosis and osteosclerosis in a beagle. (1141034)
1975

Genetic Variations for Myelofibrosis

Expression for genes affiliated with Myelofibrosis

Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Myelofibrosis

Search GEO for disease gene expression data for Myelofibrosis.

Pathways for genes affiliated with Myelofibrosis

Sources:
52QIAGEN, 30KEGG, 54Reactome, 53R&D Systems, 12EMD Millipore, 38NCBI BioSystems Database, 4Cell Signaling Technology
See all sources

Pathways related to Myelofibrosis according to GeneCards/GeneDecks:

(show all 28)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Hide members
10.6THPO, KIT, IL11, IL3, FGF2, PF4
2
Hide members
10.6FLT3, THPO, STAT5A, BMP6, IL3, JAK2
3
Hide members
10.6JAK2, LIF, BMP6, PF4, FGF2, IL3
4
Hide members
10.6IL11, IL3, LIF, MPL, FLT3, STAT5A
5
Hide members
10.6FGF2, STAT5A, BMP6, FLT3, JAK2, IL3
610.6IL3, EPO, LIF, MPL, STAT5A, IFNA2
710.5IL3, IFNA2, JAK2, FGF2, KIT, EPO
8
Hide members
10.5JAK2, GATA1, MPL, IFNA2, CD177, PF4
9
Hide members
10.5THPO, LIF, BMP6, FGF2, IL3, KIT
10
Hide members
10.5THPO, KIT, IL3, FGF2, FLT3, BMP6
11
Hide members
10.5IL3, THPO, KIT, FGF2, FLT3, BMP6
1210.5IL11, IL3, THPO, KIT, EPO, FLT3
13
Hide members
10.5THPO, MPL, STAT5A, JAK2
14
Development Thrombopoetin signaling via JAK-STAT pathway
Hide members
10.5JAK2, THPO, MPL, STAT5A
1510.5KIT, JAK2, FLT3, FGF2
16
Hide members
10.5STAT5A, JAK2, EPO, KIT
17
Hide members
10.5FGF2, KIT, THPO, FLT3
18
Hide members
10.5KIT, FGF2, STAT5A, JAK2
1910.5JAK2, GATA1, STAT5A, IL3
20
Hide members
10.5IL3, JAK2, THPO
21
Hide members
10.5FGF2, THPO, BMP6, IL3
22
Hide members
10.5IL3, JAK2, STAT5A, FLT3
23
Hide members
10.5IFNA2, JAK2, STAT5A, IL3
24
Development EPO-induced Jak-STAT pathway
Hide members
10.5STAT5A, JAK2, EPO
25
Hide members
10.5MPL, THPO
26
Immune response IL-2 activation and signaling pathway
Hide members
10.5IL3, JAK2, STAT5A
2710.5FGF2, IL3, IL11, STAT5A
28
Hide members
10.5BMP6, THPO

Compounds for genes affiliated with Myelofibrosis

Sources:
45Novoseek, 24HMDB, 50PharmGKB, 11DrugBank, 29IUPHAR, 60Tocris Bioscience, 2BitterDB
See all sources

Compounds related to Myelofibrosis according to GeneCards/GeneDecks:

(show top 50)    (show all 151)
idCompoundScoreTop Affiliating Genes
1tyrosine4511.1MPL, STAT5A, JAK2, BMP6, TNFRSF11B, IFNA2
2vegf4511.0THPO, IL11, FGF2, KIT, PF4, EPO
3gp 1304511.0TNFRSF11B, BMP6, JAK2, STAT5A, FLT3, MPL
4thymidine45 2412.0JAK2, BMP6, IFNA2, STAT5A, PF4, THPO
5retinoic acid45 2412.0JAK2, THPO, HMGA2, IL11, IL3, BMP6
6phosphatidylinositol4511.0FLT3, THPO, KIT, IL11, IL3, FGF2
7cytarabine45 50 1113.0EPO, IL3, IL11, KIT, THPO, LIF
8agar4511.0LIF, MPL, IFNA2, THPO, FGF2, PF4
9methylcellulose4511.0IL11, THPO, FLT3, LIF, EPO, FGF2
10anagrelide45 1112.0IFNA2, JAK2, MPL, EPO, PF4, THPO
11hydroxyurea45 50 1113.0PF4, THPO, GATA1, EPO, IL3, IFNA2
12cyclosporin a45 29 6013.0JAK2, IL3, FGF2, IL11, FKBP5, LIF
13cysteine4511.0IL3, STAT5A, JAK2, MPL, AHSG, PF4
14imatinib45 50 1113.0FLT3, THPO, STAT5A, IL3, JAK2, KIT
15steroid4511.0FKBP5, GATA1, IFNA2, THPO, LIF, STAT5A
16rapamycin4511.0STAT5A, FLT3, JAK2, BMP6, EPO, THPO
17filgrastim45 1111.9THPO, IL11, IL3, EPO, IFNA2, LIF
18tgf beta14510.9IL11, THPO, PF4, TNFRSF11B, FLT3, BMP6
19estrogen4510.9AHSG, THPO, GATA1
20gm-csf45 2911.9THPO, STAT5A, IL11, LIF
21doxorubicin45 50 1112.9HMGA2, KIT, IL11, IL3, GATA1, FLT3
22pixy3214510.9THPO, EPO, IL3, IL11, FLT3
235fluorouracil4510.9THPO, MPL, KIT, IL11, IL3, PF4
24cycloheximide4510.9GATA1, FKBP5
25aspartate4510.9IL11, FLT3, GATA1, STAT5A, BMP6, JAK2
2612-o-tetradecanoylphorbol 13-acetate4510.9GATA1, IFNA2, IL11, IL3, PF4, LIF
27hydrocortisone45 2 60 1113.9FGF2, TNFRSF11B, LIF, STAT5A, EPO
28pd 98,0594510.9STAT5A, JAK2, FGF2, IL3, KIT, BMP6
29ly2940024510.9STAT5A, FGF2, BMP6, IL3, THPO, TNFRSF11B
30herbimycin a45 6011.9IL3, FGF2, BMP6, JAK2, STAT5A, IL11
31alanine4510.9STAT5A, MPL, PF4, JAK2, FGF2, IL3
32dexamethasone45 50 29 1113.9IL3, TNFRSF11B, FKBP5, FGF2, BMP6, LIF
33carboplatin45 50 1112.9THPO, EPO, IL11, IFNA2, LIF, IL3
34actinomycin d4510.9KIT, GATA1, JAK2, LIF, FGF2, IL3
35indomethacin45 60 29 1113.8PF4
36calcitriol45 60 11 2413.8IL11, BMP6, LIF, EPO, TNFRSF11B, IL3
37polyethylene glycol4510.8IFNA2, BMP6, PF4, IL11, THPO, MPL
38progesterone45 60 29 11 2414.8KIT, IL11, FKBP5, LIF, STAT5A, GATA1
39il 114510.8LIF, IL11, EPO, IL3
40azathioprine45 50 2 1113.8TNFRSF11B, IL11, EPO, GATA1, IFNA2, LIF
41rantes4510.7THPO, IL3, PF4, LIF, BMP6, IL11
42lactate4510.7BMP6, FLT3, PF4, LIF, EPO, IL3
43etoposide45 50 60 1113.7IL3, THPO, IFNA2, STAT5A, FLT3, PF4
44oligonucleotide4510.7GATA1, THPO, IL11, KIT, LIF, FLT3
45ascorbic acid45 2411.6LIF, EPO, FGF2, IL3, JAK2, TNFRSF11B
46glucose4510.6AHSG, IFNA2, PF4, IL11, LIF
47sb 20358045 6011.5TNFRSF11B, BMP6, THPO, LIF, STAT5A, JAK2
48butyrate4510.5JAK2, THPO, IL11, GATA1
49ag-12964510.4FLT3, KIT, IL3, STAT5A
50amifostine45 1111.2THPO, IL11, IL3, EPO

GO Terms for genes affiliated with Myelofibrosis

Sources:
16Gene Ontology
See all sources

Cellular components related to Myelofibrosis according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1extracellular regionGO:00557610.5IL3, FGF2, PF4, AHSG, EPO, TNFRSF11B
2extracellular spaceGO:00561510.3IFNA2, IL3, FGF2, PF4, AHSG, EPO

Biological processes related to Myelofibrosis according to GeneCards/GeneDecks:

(show all 27)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of cell proliferationGO:00828410.9IL11, JAK2, FLT3, LIF, EPO, FGF2
2blood coagulationGO:00759610.9CD177, THPO, IFNA2, PF4, JAK2, GATA1
3positive regulation of tyrosine phosphorylation of Stat5 proteinGO:04252310.9JAK2, EPO, IL3, KIT
4positive regulation of peptidyl-tyrosine phosphorylationGO:05073110.9JAK2, GATA1, LIF, IL3, IL11
5positive regulation of tyrosine phosphorylation of Stat3 proteinGO:04251710.9JAK2, IFNA2, KIT, LIF
6peptidyl-tyrosine phosphorylationGO:01810810.9KIT, JAK2, FLT3, STAT5A
7positive regulation of transcription from RNA polymerase II promoterGO:04594410.9FGF2, LIF, GATA1, IL11, HMGA2, BMP6
8cytokine-mediated signaling pathwayGO:01922110.8JAK2, FLT3, PF4, KIT, IFNA2
9positive regulation of MAPK cascadeGO:04341010.8FLT3, LIF, IL11, KIT
10embryonic hemopoiesisGO:03516210.8IL3, KIT, GATA1
11negative regulation of cell proliferationGO:00828510.8JAK2, FGF2, FLT3, LIF, GATA1
12erythrocyte differentiationGO:03021810.8KIT, GATA1, JAK2
13positive regulation of phosphatidylinositol 3-kinase activityGO:04355210.8FLT3, FGF2, KIT
14positive regulation of phosphatidylinositol 3-kinase cascadeGO:01406810.8KIT, FLT3, JAK2
15tyrosine phosphorylation of Stat3 proteinGO:04250310.8LIF, JAK2
16myeloid progenitor cell differentiationGO:00231810.7FLT3, KIT
17mammary gland epithelium developmentGO:06118010.7STAT5A, JAK2
18platelet activationGO:03016810.7PF4, MPL, THPO, IL11
19positive regulation of phospholipase C activityGO:01086310.7FGF2, KIT
20megakaryocyte differentiationGO:03021910.7GATA1, IL11
21dendritic cell differentiationGO:09702810.6FLT3, GATA1
22positive regulation of tyrosine phosphorylation of Stat1 proteinGO:04251110.6KIT, LIF
23cell-cell signalingGO:00726710.6IL11, IL3, IFNA2, GATA1
24male gonad developmentGO:00858410.5HMGA2, KIT, GATA1
25cellular response to thyroid hormone stimulusGO:09706710.5KIT, GATA1
26negative regulation of hormone secretionGO:04688810.4LIF, IL11
27positive regulation of macrophage differentiationGO:04565110.2LIF, PF4

Molecular functions related to Myelofibrosis according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1C2H2 zinc finger domain bindingGO:07074210.5HMGA2, GATA1
2cytokine activityGO:00512510.4THPO, IFNA2, TNFRSF11B, BMP6, LIF, FGF2
3growth factor activityGO:00808310.2BMP6, LIF, FGF2, IL3, IL11, THPO

Products for genes affiliated with Myelofibrosis

  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Myelofibrosis

3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
29IUPHAR
30KEGG
35MeSH
36MESH via Orphanet
37MGI
40NCIt
41NDF-RT
44NINDS
45Novoseek
47OMIM
48OMIM via Orphanet
51PubMed
52QIAGEN
58SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet